- Recruiting
NCT03941860: Phase 3 - EAA171 - OPTIMUM - Addition of Ixazomib to Lenalidomide in Residual Myeloma
Updated: Oct 4, 2022
EAA171
OPTIMUM
NCT03941860: Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
NCT03941860: Phase 3 - Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.
Sponsor
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT03941860
Official Title: Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)
First Posted : May 8, 2019
Click here for details on ClinicalTrials.Gov
EAA171 / OPTIMUM Home Page - ECOG-ACRIN Cancer Research Group